460 related articles for article (PubMed ID: 27341313)
1. The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era.
Blaker YN; Spetalen S; Brodtkorb M; Lingjaerde OC; Beiske K; Østenstad B; Sander B; Wahlin BE; Melen CM; Myklebust JH; Holte H; Delabie J; Smeland EB
Br J Haematol; 2016 Oct; 175(1):102-14. PubMed ID: 27341313
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of tissue-infiltrating immune cells in tumor microenvironment of follicular lymphoma: A meta-analysis.
Xie M; Jiang Q; Zhao S; Zhao J; Ye X; Qian W
Int Immunopharmacol; 2020 Aug; 85():106684. PubMed ID: 32540726
[TBL] [Abstract][Full Text] [Related]
3. Rituximab treatment circumvents the prognostic impact of tumor-infiltrating T-cells in follicular lymphoma patients.
Xerri L; Huet S; Venstrom JM; Szafer-Glusman E; Fabiani B; Canioni D; Chassagne-Clément C; Dartigues-Cuilléres P; Charlotte F; Laurent C; Gelas-Dore B; Bolen CR; Punnoose E; Bouabdallah R; Brice P; Morschhauser F; Cartron G; Olive D; Salles G;
Hum Pathol; 2017 Jun; 64():128-136. PubMed ID: 28414090
[TBL] [Abstract][Full Text] [Related]
4. Immune infiltrate diversity confers a good prognosis in follicular lymphoma.
Tsakiroglou AM; Astley S; Dave M; Fergie M; Harkness E; Rosenberg A; Sperrin M; West C; Byers R; Linton K
Cancer Immunol Immunother; 2021 Dec; 70(12):3573-3585. PubMed ID: 33929583
[TBL] [Abstract][Full Text] [Related]
5. Follicular programmed death 1-positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma.
Richendollar BG; Pohlman B; Elson P; Hsi ED
Hum Pathol; 2011 Apr; 42(4):552-7. PubMed ID: 21237493
[TBL] [Abstract][Full Text] [Related]
6. Pattern of CD14+ follicular dendritic cells and PD1+ T cells independently predicts time to transformation in follicular lymphoma.
Smeltzer JP; Jones JM; Ziesmer SC; Grote DM; Xiu B; Ristow KM; Yang ZZ; Nowakowski GS; Feldman AL; Cerhan JR; Novak AJ; Ansell SM
Clin Cancer Res; 2014 Jun; 20(11):2862-72. PubMed ID: 24727328
[TBL] [Abstract][Full Text] [Related]
7. The incidence of biopsy-proven transformation in follicular lymphoma in the rituximab era. A retrospective analysis from the Czech Lymphoma Study Group (CLSG) database.
Janikova A; Bortlicek Z; Campr V; Kopalova N; Benesova K; Hamouzova M; Belada D; Prochazka V; Pytlik R; Vokurka S; Pirnos J; Duras J; Mocikova H; Mayer J; Trneny M
Ann Hematol; 2018 Apr; 97(4):669-678. PubMed ID: 29318369
[TBL] [Abstract][Full Text] [Related]
8. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
[TBL] [Abstract][Full Text] [Related]
9. Analysis of dendritic cell subpopulations in follicular lymphoma with respect to the tumor immune microenvironment.
Chevalier N; Mueller M; Mougiakakos D; Ihorst G; Marks R; Schmitt-Graeff A; Veelken H
Leuk Lymphoma; 2016 Sep; 57(9):2150-60. PubMed ID: 26757600
[TBL] [Abstract][Full Text] [Related]
10. Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group.
Alonso-Álvarez S; Magnano L; Alcoceba M; Andrade-Campos M; Espinosa-Lara N; Rodríguez G; Mercadal S; Carro I; Sancho JM; Moreno M; Salar A; García-Pallarols F; Arranz R; Cannata J; Terol MJ; Teruel AI; Rodríguez A; Jiménez-Ubieto A; González de Villambrosia S; Bello JL; López L; Monsalvo S; Novelli S; de Cabo E; Infante MS; Pardal E; García-Álvarez M; Delgado J; González M; Martín A; López-Guillermo A; Caballero MD
Br J Haematol; 2017 Sep; 178(5):699-708. PubMed ID: 28782811
[TBL] [Abstract][Full Text] [Related]
11. High TNFRSF14 and low BTLA are associated with poor prognosis in Follicular Lymphoma and in Diffuse Large B-cell Lymphoma transformation.
Carreras J; Lopez-Guillermo A; Kikuti YY; Itoh J; Masashi M; Ikoma H; Tomita S; Hiraiwa S; Hamoudi R; Rosenwald A; Leich E; Martinez A; Roncador G; Villamor N; Colomo L; Perez P; Tsuji NM; Campo E; Nakamura N
J Clin Exp Hematop; 2019; 59(1):1-16. PubMed ID: 30918139
[TBL] [Abstract][Full Text] [Related]
12. Follicular Lymphoma: The Role of the Tumor Microenvironment in Prognosis.
Sugimoto T; Watanabe T
J Clin Exp Hematop; 2016; 56(1):1-19. PubMed ID: 27334853
[TBL] [Abstract][Full Text] [Related]
13. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource.
Link BK; Maurer MJ; Nowakowski GS; Ansell SM; Macon WR; Syrbu SI; Slager SL; Thompson CA; Inwards DJ; Johnston PB; Colgan JP; Witzig TE; Habermann TM; Cerhan JR
J Clin Oncol; 2013 Sep; 31(26):3272-8. PubMed ID: 23897955
[TBL] [Abstract][Full Text] [Related]
14. High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma.
Carreras J; Lopez-Guillermo A; Roncador G; Villamor N; Colomo L; Martinez A; Hamoudi R; Howat WJ; Montserrat E; Campo E
J Clin Oncol; 2009 Mar; 27(9):1470-6. PubMed ID: 19224853
[TBL] [Abstract][Full Text] [Related]
15. Follicular Lymphoma Microenvironment Traits Associated with Event-Free Survival.
Tumedei MM; Piccinini F; Azzali I; Pirini F; Bravaccini S; De Matteis S; Agostinelli C; Castellani G; Zanoni M; Cortesi M; Vergani B; Leone BE; Righi S; Gazzola A; Casadei B; Gentilini D; Calzari L; Limarzi F; Sabattini E; Pession A; Tazzari M; Bertuzzi C
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373066
[TBL] [Abstract][Full Text] [Related]
16. Good prognosis for follicular lymphoma with estrogen receptor α-positive follicular dendritic cells.
Ohe R; Meng HX; Yamada A; Ye Aung N; Kabasawa T; Tamura Y; Utsunomiya A; Tamazawa N; Kawamura I; Kitaoka T; Suzuki K; Yanagiya R; Toubai T; Ishizawa K; Yamakawa M
Hematol Oncol; 2020 Aug; 38(3):293-300. PubMed ID: 32196124
[TBL] [Abstract][Full Text] [Related]
17. Low number of intrafollicular T cells may predict favourable response to rituximab-based immuno-chemotherapy in advanced follicular lymphoma: a secondary analysis of a randomized clinical trial.
Budau L; Wilhelm C; Moll R; Jäkel J; Hirt C; Dölken G; Maschmeyer G; Neubauer E; Strauch K; Burchert A; Herold M; Neubauer A
J Cancer Res Clin Oncol; 2019 Aug; 145(8):2149-2156. PubMed ID: 31273513
[TBL] [Abstract][Full Text] [Related]
18. The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation.
Farinha P; Al-Tourah A; Gill K; Klasa R; Connors JM; Gascoyne RD
Blood; 2010 Jan; 115(2):289-95. PubMed ID: 19901260
[TBL] [Abstract][Full Text] [Related]
19. Prognostic implications of histologic grade and intensity of Bcl-2 expression in follicular lymphomas undergoing rituximab-containing therapy.
Maeshima AM; Taniguchi H; Nomoto J; Miyamoto K; Fukuhara S; Munakata W; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Tsuda H
Hum Pathol; 2013 Nov; 44(11):2529-35. PubMed ID: 23916290
[TBL] [Abstract][Full Text] [Related]
20. Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols.
de Jong D; Koster A; Hagenbeek A; Raemaekers J; Veldhuizen D; Heisterkamp S; de Boer JP; van Glabbeke M
Haematologica; 2009 Jan; 94(1):70-7. PubMed ID: 19059937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
